A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
Latest Information Update: 23 Jan 2026
At a glance
- Drugs Sacituzumab Tirumotecan (Primary)
- Indications Thymic epithelial tumour
- Focus Therapeutic Use
Most Recent Events
- 23 Jan 2026 New trial record